Developer docs
API playgroundTry for free, no card

Search company profiles

SSI Diagnostica

Full company profile

uuid000bl4l

Namestring
SSI Diagnostica
Legal namestring
SSI Diagnostica A/S
Websiteurl
ssid.com
Company typeenum
Private
Founded yearint
1902
Descriptiontext

SSI Diagnostica Group (legally SSI Diagnostica A/S, headquartered in Hillerød, Denmark) is a privately held in vitro diagnostics (IVD) company specializing in infectious disease detection across gastrointestinal, respiratory, bloodborne, and general microbiology disease areas. Scientific roots trace to the Statens Serum Institut (founded 1902); the entity was spun out in 1998 and acquired by Adelis Equity Partners in 2016. The Group today operates five to seven integrated brand portfolios (SSI Diagnostica, TECHLAB, Beijing Genesee Biotech, CTK Biotech, Gulf Coast Scientific, InDevR, and FAN GmbH), employing approximately 600 staff across 11 sites in Denmark, the United States, and China, and delivers diagnostic solutions to more than 130 countries.

The product portfolio is split into two streams. Life Science Solutions supplies antisera, antigens, reference bacterial strains, culture media, multiplexed potency assays (VaxArray), and digital interpretation systems (CypherOne) to vaccine manufacturers, CROs, and reference laboratories — including proprietary content libraries covering 92 pneumococcus serotypes, comprehensive Salmonella coverage, and full E. coli O/H/K/F typing. Diagnostic Solutions delivers finished IVD products (lateral flow immunoassays under the QUIK CHEK platform, ELISA, the PyloPLUS urea breath test, FAN breath test devices, and the Flexicult urinalysis kit) to hospital labs, reference labs, and public health programs, with 60+ million tests produced annually.

The Group runs a hybrid go-to-market combining direct enterprise field sales in the Nordics and USA with a network of distribution partners for global reach. Revenue is generated through one-time product sales and contract manufacturing/customization services, with quote-based enterprise pricing and no disclosed subscription model. Strategic customers include GSK (vaccine development, 40+ years), US reference laboratories, and hospital networks. Revenue is approximately 850 mDKK (~$125 mUSD) on a post-Gulf Coast Scientific basis per the April 2025 acquisition announcement.

Short descriptiontext

SSI Diagnostica Group is a Danish in vitro diagnostics company developing and manufacturing infectious disease tests (gastrointestinal, respiratory, bloodborne) and life science reagents for vaccine manufacturers, clinical labs, and reference laboratories across 130+ countries, operating five brand portfolios under Adelis Equity Partners ownership.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersHillerød, Denmark
HQ citystring
Hillerød
HQ countrystring
Denmark
HQ regionstring
Europe
Markets served

Serves global market

Offices8 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
in vitro diagnostics, infectious disease testing, vaccine quality control, lateral flow assays, microbial serotyping reagents
Industry3 codes
PRIMARYHLAHAAAC
Microbiology & Infectious Disease Diagnostics (Culture/ID/AST)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAC
Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels)
SECONDARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Analytical Laboratory Instrument Manufacturing334516
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Laboratory Analytical Instruments3826
Product category
In Vitro Diagnostics
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Diagnostic Solutions Products
TypeOne Time License
Description

Finished in vitro diagnostic products including lateral flow tests, enzyme immunoassays, ELISA platforms, culture media, urea breath testing, and digital readers sold to healthcare professionals and laboratories

ssid.com
2Life Science Solutions Products
TypeOne Time License
Description

Products used by life science and pharma industry including antisera, antigens, serotyping/multiplexing kits, and instrument solutions for vaccine development and quality control

ssid.com
3Customization and Contract Manufacturing Services
TypeProfessional Services
Description

Customization and contract manufacturing services across all development stages for vaccine manufacturers and IVD industry

ssid.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

SSI Diagnostica develops, produces, and sells in vitro diagnostic products for clinical microbiology and veterinary diagnostics, organized into two complementary portfolios. Life Science Solutions provides reagents, serotyping kits, multiplexing assays, reference bacterial strains, and culture media used by vaccine manufacturers, IVD developers, and CROs. Diagnostic Solutions comprises finished IVD products—including lateral flow tests (QUIK CHEK family), ELISAs, urea breath tests, urinary antigen tests, and digital readers—used by hospital, reference, and microbiology laboratories for gastrointestinal, respiratory, and bloodborne infectious disease detection. The group also offers customization and contract manufacturing services across development stages for vaccine and IVD customers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 60 million+ diagnostic tests delivered annually
+3 more records
Product overview1 text field

SSI Diagnostica Group offers two complementary portfolios: Life Science Solutions and Diagnostic Solutions. Life Science products include antisera, antigens, serotyping/multiplexing kits, reference bacterial strains, culture media, and instrument solutions serving vaccine manufacturers, IVD industry, and CROs. Diagnostic Solutions encompass lateral flow tests (QUIK CHEK family), enzyme immunoassays (ELISA), urea breath testing, digital readers, and rapid diagnostic kits for infectious gastrointestinal, respiratory, and bloodborne diseases. The company operates five acquired brands (SSI Diagnostica, CTK Biotech, Beijing Genesee Biotech, TECHLAB, Gulf Coast Scientific, and InDevR) offering over 200 years of combined scientific expertise across more than 130 countries.

Product and service13 records
1C. DIFF QUIK CHEK COMPLETE
CategoryDiagnostic product
Description

Rapid membrane enzyme immunoassay for the simultaneous detection of Clostridioides difficile GDH antigen and toxins A and B in a single reaction well, delivering results in approximately 30 minutes for hospital and reference laboratories.

2C. difficile QUIK CHEK and ELISA Test Family
CategoryDiagnostic product
Description

Family of rapid membrane EIAs and ELISAs (C. DIFF CHEK-60, C. DIFFICILE TOX A/B II, C. DIFFICILE TOX-B TEST) for detection of GDH and toxins A/B from Clostridioides difficile in fecal specimens, used by clinical microbiology laboratories.

3Parasitology QUIK CHEK and ELISA Test Family
CategoryDiagnostic product
Description

Rapid membrane EIAs and ELISAs (GIARDIA/CRYPTOSPORIDIUM QUIK CHEK, GIARDIA/CRYPTOSPORIDIUM CHEK, GIARDIA II, CRYPTOSPORIDIUM II, TRI-COMBO PARASITE SCREEN, E. HISTOLYTICA QUIK CHEK, E. HISTOLYTICA II) for detection of Giardia, Cryptosporidium, and Entamoeba histolytica antigens in fecal specimens.

4Shiga Toxin QUIK CHEK and CHEK
CategoryDiagnostic product
Description

Rapid membrane enzyme immunoassays for the simultaneous qualitative detection and differentiation of Shiga toxin 1 (Stx1) and Shiga toxin 2 (Stx2) in a single test, used by clinical laboratories for STEC diagnostics.

5ImmuView Urinary Antigen Tests
CategoryDiagnostic product
Description

Urinary antigen tests for the detection of Streptococcus pneumoniae alone and in combination with Legionella pneumophila antigens, supporting rapid diagnosis of respiratory infections in hospital laboratories.

6Pneumococcal Antisera (92 serotypes)
CategoryLife Science product
Description

High-quality antisera for serotyping of Streptococcus pneumoniae covering 92 serotypes, used by vaccine manufacturers, reference labs, and public health authorities for vaccine development, quality control, and epidemiological surveillance.

7Salmonella Antisera and Serotyping Kits
CategoryLife Science product
Description

Comprehensive antisera range for serotyping of Salmonella serovars, supporting disease surveillance and epidemiological monitoring by reference laboratories and national health authorities.

8E. coli Antisera and Reference Strains
CategoryLife Science product
Description

Comprehensive antisera range and reference strains for all known E. coli strains covering O, H, K and F antigens, delivered in extract agar or cryogenic vials, used for surveillance and quality control.

9ImmuLex Group B Streptococcus Antisera
CategoryLife Science product
Description

Polyclonal antibodies sensitized on latex particles for rapid agglutination testing of Group B Streptococcus (Streptococcus agalactiae), used by clinical microbiology laboratories.

10Culture Media
CategoryLife Science product
Description

Broad variety of culturing media from solid agar plates to liquids in tubes, produced with high quality and precision at state-of-the-art production facilities for microbiology laboratories.

11Flexicult Urinkit
CategoryDiagnostic product
Description

Diagnostic aid for urinary tract infections, supporting diagnosis and treatment decisions in clinical settings.

12Animal Blood Products
CategoryLife Science product
Description

Blood from horses, cattle, rabbits and sheep delivered in various volumes, stabilized by defibrination or anticoagulants for laboratory use.

13Dermatophyte and C. albicans Real-Time PCR Kit
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-01
Description

Germany-based manufacturer of breath test devices for H. pylori testing. Acquisition secures critical component in breath testing workflow and strengthens SSI's European footprint. Had prior commercial and R&D partnership with Gulf Coast Scientific.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-01
Description

Colorado-based provider of advanced multiplexed solutions for vaccine testing and quality control. Acquisition adds expertise in influenza and mRNA vaccine QC testing, complementing SSI's pneumococcal vaccine testing leadership. Now exhibiting together at World Vaccine Congress.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-01
Description

Florida-based IVD company specialized in Urea Breath Testing for Helicobacter Pylori. Acquisition strengthened SSI's gastrointestinal disease testing portfolio with complementary products.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-08-01
Description

Virginia-based developer and manufacturer of rapid diagnostic tests for gastrointestinal conditions including C. difficile and H. pylori. Acquisition expanded gastric product portfolio and US market presence.

5CTK Biotech
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

California-based company providing bloodborne diagnostic solutions including Malaria, HIV, Syphilis, Dengue, Hepatitis tests. Joined SSI Group in 2020 alongside Beijing Genesee Biotech.

ssid.com
6Beijing Genesee Biotech (BGB)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Manufacturing capabilities in China established 2005. Part of 2020 acquisition alongside CTK Biotech, bringing extensive portfolio of bloodborne diagnostic solutions.

ssid.com
Strategic tierCoreTypeOthers
Description

Leading global vaccine manufacturer trusted partner for 40+ years, using SSI Diagnostica Group's high-quality reagents and quality control solutions for vaccine development.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US-based specialty microbiology and culture media manufacturer. Directly comparable to SSIDG's culture media production business and microbiology reagent offerings.

TypeDirect peer
Description

Specialty IVD company serving clinical and industrial microbiology markets with reagent kits and instruments. Comparable specialty diagnostics scale and product breadth in microbiology.

TypeBroad incumbent
Description

Global leader in clinical microbiology and industrial diagnostics, with deep overlap in infectious disease IVD, culture media, and immunoassays. Much larger and broader portfolio, but competes head-to-head with SSIDG in microbiology and GI diagnostics.

TypeDirect peer
Description

Specialty IVD and clinical chemistry company with comparable reagent and kit portfolio for clinical laboratories. Closely comparable in scale and channel mix for routine IVD products.

TypeBroad incumbent
Description

Life sciences and diagnostics company with significant applied genomics, reagents, and specialty diagnostics offerings. Overlaps with SSIDG's life science reagent business and vaccine development support.

TypeBroad incumbent
Description

Established life science and clinical diagnostics company with significant IVD reagent, quality control, and microbiology portfolios. Overlaps with SSIDG in clinical diagnostics reagents and laboratory QC.

TypeBroad incumbent
Description

Specialty IVD company with strong position in immunodiagnostics and infectious disease serology, having acquired Luminex for multiplexing. Comparable to SSIDG's Life Science Solutions in immunoassay reagents and vaccine QC adjacencies.

TypeDirect peer
Description

Specialty diagnostics company historically focused on GI infectious disease testing (C. difficile, H. pylori, enteric pathogens) — directly comparable to SSIDG's TECHLAB franchise in gastrointestinal diagnostics.

TypeBroad incumbent
Description

Large molecular diagnostics and women's health company with significant infectious disease testing presence. Competes with SSIDG in respiratory and bloodborne pathogen testing through molecular platforms.

TypeDirect peer
Description

Specialty IVD company focused on rapid immunoassays and infectious disease diagnostics, including lateral flow platforms. Directly comparable to SSIDG's QUIK CHEK business in clinical diagnostics for GI, respiratory, and bloodborne pathogens.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries6 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SSI Diagnostica

In Vitro Diagnosticsssid.com

SSI Diagnostica Group is a Danish in vitro diagnostics company developing and manufacturing infectious disease tests (gastrointestinal, respiratory, bloodborne) and life science reagents for vaccine manufacturers, clinical labs, and reference laboratories across 130+ countries, operating five brand portfolios under Adelis Equity Partners ownership.

What SSI Diagnostica does

SSI Diagnostica Group (legally SSI Diagnostica A/S, headquartered in Hillerød, Denmark) is a privately held in vitro diagnostics (IVD) company specializing in infectious disease detection across gastrointestinal, respiratory, bloodborne, and general microbiology disease areas. Scientific roots trace to the Statens Serum Institut (founded 1902); the entity was spun out in 1998 and acquired by Adelis Equity Partners in 2016. The Group today operates five to seven integrated brand portfolios (SSI Diagnostica, TECHLAB, Beijing Genesee Biotech, CTK Biotech, Gulf Coast Scientific, InDevR, and FAN GmbH), employing approximately 600 staff across 11 sites in Denmark, the United States, and China, and delivers diagnostic solutions to more than 130 countries.

The product portfolio is split into two streams. Life Science Solutions supplies antisera, antigens, reference bacterial strains, culture media, multiplexed potency assays (VaxArray), and digital interpretation systems (CypherOne) to vaccine manufacturers, CROs, and reference laboratories — including proprietary content libraries covering 92 pneumococcus serotypes, comprehensive Salmonella coverage, and full E. coli O/H/K/F typing. Diagnostic Solutions delivers finished IVD products (lateral flow immunoassays under the QUIK CHEK platform, ELISA, the PyloPLUS urea breath test, FAN breath test devices, and the Flexicult urinalysis kit) to hospital labs, reference labs, and public health programs, with 60+ million tests produced annually.

The Group runs a hybrid go-to-market combining direct enterprise field sales in the Nordics and USA with a network of distribution partners for global reach. Revenue is generated through one-time product sales and contract manufacturing/customization services, with quote-based enterprise pricing and no disclosed subscription model. Strategic customers include GSK (vaccine development, 40+ years), US reference laboratories, and hospital networks. Revenue is approximately 850 mDKK (~$125 mUSD) on a post-Gulf Coast Scientific basis per the April 2025 acquisition announcement.

SSI Diagnostica firmographics

Firmographics
Name
SSI Diagnostica
Legal name
SSI Diagnostica A/S
Website
https://ssid.com
Company type
Private
Founded year
1902
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
SSI Diagnostica Group is a Danish in vitro diagnostics company developing and manufacturing infectious disease tests (gastrointestinal, respiratory, bloodborne) and life science reagents for vaccine manufacturers, clinical labs, and reference laboratories across 130+ countries, operating five brand portfolios under Adelis Equity Partners ownership.
Ownership category
akta.pro rank

SSI Diagnostica industry classification

Industry
Product category
In Vitro Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAHAAAC
Microbiology & Infectious Disease Diagnostics (Culture/ID/AST)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAC
Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels)
SECONDARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)

Keywords

  • In vitro diagnostics
  • Infectious disease testing
  • Vaccine quality control
  • Lateral flow assays
  • Microbial serotyping reagents

Where SSI Diagnostica is headquartered

Location

Headquarters

HQ city
Hillerød
HQ country
Denmark
HQ region
Europe

Offices8 records

Markets served

SSI Diagnostica business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Diagnostic Solutions Products: Finished in vitro diagnostic products including lateral flow tests, enzyme immunoassays, ELISA platforms, culture media, urea breath testing, and digital readers sold to healthcare professionals and laboratories
  2. Life Science Solutions Products: Products used by life science and pharma industry including antisera, antigens, serotyping/multiplexing kits, and instrument solutions for vaccine development and quality control
  3. Customization and Contract Manufacturing Services: Customization and contract manufacturing services across all development stages for vaccine manufacturers and IVD industry

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

SSI Diagnostica product offering

Product offering

Core offering

SSI Diagnostica develops, produces, and sells in vitro diagnostic products for clinical microbiology and veterinary diagnostics, organized into two complementary portfolios. Life Science Solutions provides reagents, serotyping kits, multiplexing assays, reference bacterial strains, and culture media used by vaccine manufacturers, IVD developers, and CROs. Diagnostic Solutions comprises finished IVD products—including lateral flow tests (QUIK CHEK family), ELISAs, urea breath tests, urinary antigen tests, and digital readers—used by hospital, reference, and microbiology laboratories for gastrointestinal, respiratory, and bloodborne infectious disease detection. The group also offers customization and contract manufacturing services across development stages for vaccine and IVD customers.

Product overview

SSI Diagnostica Group offers two complementary portfolios: Life Science Solutions and Diagnostic Solutions. Life Science products include antisera, antigens, serotyping/multiplexing kits, reference bacterial strains, culture media, and instrument solutions serving vaccine manufacturers, IVD industry, and CROs. Diagnostic Solutions encompass lateral flow tests (QUIK CHEK family), enzyme immunoassays (ELISA), urea breath testing, digital readers, and rapid diagnostic kits for infectious gastrointestinal, respiratory, and bloodborne diseases. The company operates five acquired brands (SSI Diagnostica, CTK Biotech, Beijing Genesee Biotech, TECHLAB, Gulf Coast Scientific, and InDevR) offering over 200 years of combined scientific expertise across more than 130 countries.

Differentiator

Problem solved

Functional benefit

Products and services

  • C. DIFF QUIK CHEK COMPLETE Rapid membrane enzyme immunoassay for the simultaneous detection of Clostridioides difficile GDH antigen and toxins A and B in a single reaction well, delivering results in approximately 30 minutes for hospital and reference laboratories.
  • C. difficile QUIK CHEK and ELISA Test Family Family of rapid membrane EIAs and ELISAs (C. DIFF CHEK-60, C. DIFFICILE TOX A/B II, C. DIFFICILE TOX-B TEST) for detection of GDH and toxins A/B from Clostridioides difficile in fecal specimens, used by clinical microbiology laboratories.
  • Parasitology QUIK CHEK and ELISA Test Family Rapid membrane EIAs and ELISAs (GIARDIA/CRYPTOSPORIDIUM QUIK CHEK, GIARDIA/CRYPTOSPORIDIUM CHEK, GIARDIA II, CRYPTOSPORIDIUM II, TRI-COMBO PARASITE SCREEN, E. HISTOLYTICA QUIK CHEK, E. HISTOLYTICA II) for detection of Giardia, Cryptosporidium, and Entamoeba histolytica antigens in fecal specimens.
  • Shiga Toxin QUIK CHEK and CHEK Rapid membrane enzyme immunoassays for the simultaneous qualitative detection and differentiation of Shiga toxin 1 (Stx1) and Shiga toxin 2 (Stx2) in a single test, used by clinical laboratories for STEC diagnostics.
  • ImmuView Urinary Antigen Tests Urinary antigen tests for the detection of Streptococcus pneumoniae alone and in combination with Legionella pneumophila antigens, supporting rapid diagnosis of respiratory infections in hospital laboratories.
  • Pneumococcal Antisera (92 serotypes) High-quality antisera for serotyping of Streptococcus pneumoniae covering 92 serotypes, used by vaccine manufacturers, reference labs, and public health authorities for vaccine development, quality control, and epidemiological surveillance.
  • Salmonella Antisera and Serotyping Kits Comprehensive antisera range for serotyping of Salmonella serovars, supporting disease surveillance and epidemiological monitoring by reference laboratories and national health authorities.
  • E. coli Antisera and Reference Strains Comprehensive antisera range and reference strains for all known E. coli strains covering O, H, K and F antigens, delivered in extract agar or cryogenic vials, used for surveillance and quality control.
  • ImmuLex Group B Streptococcus Antisera Polyclonal antibodies sensitized on latex particles for rapid agglutination testing of Group B Streptococcus (Streptococcus agalactiae), used by clinical microbiology laboratories.
  • Culture Media Broad variety of culturing media from solid agar plates to liquids in tubes, produced with high quality and precision at state-of-the-art production facilities for microbiology laboratories.
  • Flexicult Urinkit Diagnostic aid for urinary tract infections, supporting diagnosis and treatment decisions in clinical settings.
  • Animal Blood Products Blood from horses, cattle, rabbits and sheep delivered in various volumes, stabilized by defibrination or anticoagulants for laboratory use.
  • Dermatophyte and C. albicans Real-Time PCR Kit

Quantifiable outcome

  • 60 million+ diagnostic tests delivered annually
  • +3 more outcomes

Companies that use SSI Diagnostica

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles4 records

SSI Diagnostica technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

SSI Diagnostica partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core.

  • FAN GmbHcoreStrategic or Co-development Partner · 1 May 2026Germany-based manufacturer of breath test devices for H. pylori testing. Acquisition secures critical component in breath testing workflow and strengthens SSI's European footprint. Had prior commercial and R&D partnership with Gulf Coast Scientific.
  • InDevRcoreStrategic or Co-development Partner · 1 February 2026Colorado-based provider of advanced multiplexed solutions for vaccine testing and quality control. Acquisition adds expertise in influenza and mRNA vaccine QC testing, complementing SSI's pneumococcal vaccine testing leadership. Now exhibiting together at World Vaccine Congress.
  • Gulf Coast ScientificcoreStrategic or Co-development Partner · 1 April 2025Florida-based IVD company specialized in Urea Breath Testing for Helicobacter Pylori. Acquisition strengthened SSI's gastrointestinal disease testing portfolio with complementary products.
  • TechLab, Inc.coreStrategic or Co-development Partner · 1 August 2022Virginia-based developer and manufacturer of rapid diagnostic tests for gastrointestinal conditions including C. difficile and H. pylori. Acquisition expanded gastric product portfolio and US market presence.
  • CTK BiotechcoreStrategic or Co-development Partner · 1 January 2020California-based company providing bloodborne diagnostic solutions including Malaria, HIV, Syphilis, Dengue, Hepatitis tests. Joined SSI Group in 2020 alongside Beijing Genesee Biotech.
  • Beijing Genesee Biotech (BGB)coreStrategic or Co-development Partner · 1 January 2020Manufacturing capabilities in China established 2005. Part of 2020 acquisition alongside CTK Biotech, bringing extensive portfolio of bloodborne diagnostic solutions.
  • GSKcoreOthersLeading global vaccine manufacturer trusted partner for 40+ years, using SSI Diagnostica Group's high-quality reagents and quality control solutions for vaccine development.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

SSI Diagnostica competitors and assessment

Company assessment

Direct peers

  • Hardy Diagnostics: US-based specialty microbiology and culture media manufacturer. Directly comparable to SSIDG's culture media production business and microbiology reagent offerings.
  • ELITechGroup: Specialty IVD company serving clinical and industrial microbiology markets with reagent kits and instruments. Comparable specialty diagnostics scale and product breadth in microbiology.
  • Sekisui Diagnostics: Specialty IVD and clinical chemistry company with comparable reagent and kit portfolio for clinical laboratories. Closely comparable in scale and channel mix for routine IVD products.
  • Meridian Bioscience: Specialty diagnostics company historically focused on GI infectious disease testing (C. difficile, H. pylori, enteric pathogens) — directly comparable to SSIDG's TECHLAB franchise in gastrointestinal diagnostics.
  • QuidelOrtho: Specialty IVD company focused on rapid immunoassays and infectious disease diagnostics, including lateral flow platforms. Directly comparable to SSIDG's QUIK CHEK business in clinical diagnostics for GI, respiratory, and bloodborne pathogens.

Broad incumbents

  • bioMérieux: Global leader in clinical microbiology and industrial diagnostics, with deep overlap in infectious disease IVD, culture media, and immunoassays. Much larger and broader portfolio, but competes head-to-head with SSIDG in microbiology and GI diagnostics.
  • Revvity (formerly PerkinElmer): Life sciences and diagnostics company with significant applied genomics, reagents, and specialty diagnostics offerings. Overlaps with SSIDG's life science reagent business and vaccine development support.
  • Bio-Rad Laboratories: Established life science and clinical diagnostics company with significant IVD reagent, quality control, and microbiology portfolios. Overlaps with SSIDG in clinical diagnostics reagents and laboratory QC.
  • DiaSorin: Specialty IVD company with strong position in immunodiagnostics and infectious disease serology, having acquired Luminex for multiplexing. Comparable to SSIDG's Life Science Solutions in immunoassay reagents and vaccine QC adjacencies.
  • Hologic: Large molecular diagnostics and women's health company with significant infectious disease testing presence. Competes with SSIDG in respiratory and bloodborne pathogen testing through molecular platforms.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

SSI Diagnostica social profiles

Digital presence

SSI Diagnostica compliance and trust

Trust signal

Compliance4 records

SSI Diagnostica financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SSI Diagnostica leadership team

Management profile

Number of profiles

Profiles9 records

SSI Diagnostica subsidiaries and ownership

Company hierarchy

Subsidiaries6 records

SSI Diagnostica funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SSI Diagnostica M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SSI Diagnostica

What does SSI Diagnostica do?

SSI Diagnostica develops, produces, and sells in vitro diagnostic products for clinical microbiology and veterinary diagnostics, organized into two complementary portfolios. Life Science Solutions provides reagents, serotyping kits, multiplexing assays, reference bacterial strains, and culture media used by vaccine manufacturers, IVD developers, and CROs. Diagnostic Solutions comprises finished IVD products—including lateral flow tests (QUIK CHEK family), ELISAs, urea breath tests, urinary antigen tests, and digital readers—used by hospital, reference, and microbiology laboratories for gastrointestinal, respiratory, and bloodborne infectious disease detection. The group also offers customization and contract manufacturing services across development stages for vaccine and IVD customers.

Is SSI Diagnostica a public or private company?

SSI Diagnostica is a private company. It is classified as private equity controlled and is currently operating.

When was SSI Diagnostica founded?

SSI Diagnostica was founded in 1902. It employs 1,001 to 5,000 people.

Where is SSI Diagnostica based?

SSI Diagnostica is headquartered in Hillerød, Denmark, in the Europe region.

How does SSI Diagnostica make money?

Three revenue lines are on record. Diagnostic Solutions Products are the primary driver. The others are life Science Solutions Products and customization and Contract Manufacturing Services.

Who are SSI Diagnostica's main competitors?

Direct peers on record are Hardy Diagnostics, ELITechGroup, Sekisui Diagnostics, Meridian Bioscience and QuidelOrtho. Broad incumbents are bioMérieux, Revvity (formerly PerkinElmer), Bio-Rad Laboratories, DiaSorin and Hologic.

Does SSI Diagnostica have an API?

No public API is recorded for SSI Diagnostica.

What industry is SSI Diagnostica in?

SSI Diagnostica's product category is In Vitro Diagnostics. Its primary akta.pro industry code is HLAHAAAC, Microbiology & Infectious Disease Diagnostics (Culture/ID/AST), with a secondary code of HLAAALAC, Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceSSI Diagnostica Group strengthens life science portfolio for vaccine development and quality control with acquisition of US-based multiplexing companySSI Diagnostica Group, a Copenhagen-based company specializing in infectious disease testing solutions, has acquired InDevR, a Colorado-based provider of advanced multiplexed solutions for vaccine testing and quality control. The acquisition strengthens SSI Diagnostica Group's leadership in pneumococcal vaccine QC testing while adding InDevR's expertise in influenza and mRNA vaccine QC testing to its Life Science portfolio. The deal aligns with SSI Diagnostica Group's M&A strategy to expand its global footprint and accelerate growth in the life sciences segment.EIN PresswireSSI Diagnostica Group acquires US-based multiplexing company to strengthen portfolio for vaccine development and QCSSI Diagnostica Group, a Copenhagen-based infectious disease solutions company, has announced the acquisition of InDevR, a Colorado-based provider of advanced multiplexed solutions for vaccine testing and quality control. The acquisition adds InDevR's multiplexing technology and expertise in influenza and mRNA vaccine QC testing to SSI Diagnostica Group's Life Science portfolio, complementing its existing leadership in pneumococcal vaccine testing. The deal represents a continuation of SSI Diagnostica Group's M&A strategy to expand its global footprint and strengthen its offerings in the vaccine development and disease surveillance markets.IndevrSSI Diagnostica Group Acquires InDevRSSI Diagnostica Group, a Copenhagen-based company specializing in infectious disease testing solutions, has acquired InDevR, a Colorado-based provider of advanced multiplexing solutions for vaccine testing and quality control. The acquisition strengthens SSI Diagnostica Group's leadership in pneumococcal vaccine QC testing while adding expertise in influenza and mRNA vaccine quality control to its Life Science Solutions portfolio. The deal represents a continuation of SSI Diagnostica Group's M&A strategy to expand its global footprint and portfolio offerings in the infectious disease solutions market.PR NewswirePharos Capital Sells TechLab, Inc. to SSI DiagnosticaPharos Capital Group has sold its stake in portfolio company TechLab, Inc. to SSI Diagnostica, a diagnostics manufacturer based in Denmark and owned by Adelis Equity. This transaction marks the third exit from Pharos's third fund, with TechLab continuing to operate its U.S. facilities and retaining its existing management team. Terms of the deal were not disclosed.